Brief: Ceapro Initiates Phase 1-2A Study Assessing Avenanthramides For Potential Applications In Inflammation Based Diseases
27/11/2023 14:22
Nov 27 (Reuters) - Ceapro Inc CZO.V :
* CEAPRO INC. INITIATES PHASE 1-2A STUDY ASSESSING ITS
FLAGSHIP
PRODUCT AVENANTHRAMIDES FOR POTENTIAL APPLICATIONS IN
INFLAMMATION BASED DISEASES
Source text for Eikon: ID:nGNX1wC2Tm
Further company coverage: CZO.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ceapro
See all newsBrief: Aeterna Zentaris Announces Details Regarding Transaction with Ceapro
Brief: Ceapro Receives Final Court Approval For Merger With Aeterna Zentaris
Brief: Aeterna Zentaris And Ceapro Announce Merger Of Equals To Create Diversified Biopharmaceutical Company
Brief: Ceapro Inc. Reports 2023 Third Quarter And Nine-Month Financial Results And Operational Highlights
Brief: Ceapro Initiates Phase 1-2A Study Assessing Avenanthramides For Potential Applications In Inflammation Based Diseases